Neointimal formation following drug-eluting stents: Physiology, timeline, and the influence of drug delivery systems

Reviews in Cardiovascular Medicine

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Young, John J ^a  

^a Swedish Heart and Vascular Institute   (United States)

Author keywords

Bare metal stents; Drug eluting stents; Restenosis; Thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; NITRIC OXIDE DONOR; PACLITAXEL; RAPAMYCIN; TAXANE DERIVATIVE;

ANEURYSM; ARTERY INTIMA PROLIFERATION; BARE METAL STENT; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; GENE THERAPY; HYPERSENSITIVITY; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; STENT; THROMBOSIS; VASCULAR PATENCY;

BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG DELIVERY SYSTEMS; GRAFT OCCLUSION, VASCULAR; HUMANS; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; STENTS; TIME FACTORS; TUNICA INTIMA;

EID: 33947603862     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Libby P. Inflammation In atherosclerosis. Nature. 2002;420:868-874.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352:1685-1695.
3. Kuntz RE, Gibson CM, Nobuyoshi M, Bairn DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. 1993; 21:15-25.
4. Schwartz RS, Edwards WD, Bailey KR, et al. Differential neointimal response to coronary artery injury in pigs and dogs. Implications for restenosis models. Arterioscler Thromb. 1994; 14:395-400.
5. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents. J Am Coll Cardiol. 2004;44:1373-1385.
6. Taylor AJ, Gorman PD, Kenwood B, et al. Comparison of four stent designs on arterial injury, cellular proliferation, neointima formation, and arterial dimensions in an experimental porcine model. Catheter Cardiovasc Interv. 2001; 53:420-425.
7. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111:2257-2273.
8. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769-1776.
9. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
10. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-1193.
11. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
12. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005;111:1040-1044.
13. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
14. Arnal I, Wade RH. How does Taxol stabilize microtubules? Curr Biol. 1995;5:900-908.
15. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 2000;36:2325-2332.
16. Grube E, Silber S, Hauptmann KE, et al. TAXUS 1: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
17. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Eng J Med. 2004; 350:221-231.
18. Hwang CW, Edelman ER. Arterial ultrastructure influences transport of locally delivered drugs. Circ Res. 2002;90:826-832.
19. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA. 2004;101:9463-9467.
20. Hwang CW, Levin AD, Jonas M, et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation. 2005;111:1619-1626.
21. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004;5:9-15.
22. van Beusekom HM, Whelan DM, Hofma SH, et al. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol. 1998;32:1109-1117.
23. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents In humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
24. Kotani JI, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents. Angioscopic findings. J Am Coll Cardiol. 2006;47:2108-2111.
25. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation. 2005; 112:270-278.
26. Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol. 2006; 48:21-31.
27. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
28. Ong ATL, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:947-953.
29. Ong ATL, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092.
30. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959.
31. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056-1061.
32. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108:1701-1706.
33. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Results from the PREMIER registry. Circulation. 2006; 113:2803-2809.
34. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168.
35. Feres F, Costa JR, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv. 2006;68:83-88.
36. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents. A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-181.
37. Rogers C, Parikh S, Siefert P, Edelman ER. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation. 1996;94:2909-2914.
38. Mintz GS, Weissman NJ. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol. 2006;48:421-429.
39. Nugent HM, Edelman ER. Tissue engineering therapy for cardiovascular disease. Circ Res. 2003;92:1068-1078.
40. von der Leyen H, Gibbons G, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 1995;92:1137-1141.
41. New G, Moses J, Roubin G, et al. Estrogen-eluting, phosphorylcholine- coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv. 2002;57:266-271.
42. Abizaid A, Albertal M, Costa MA, et al. First human experience with the 17-beta-estradiol-eluting stent: the Estrogen and Stents to Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol. 2004;43:1118-1121.
43. Aoki J, Serruys PW, van Beusekom HM, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol. 2005;45:1574-1579.
44. Walter DH, Cejna M, Diaz-Sandoval L, et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation. 2004;110: 36-45.
45. Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J. 2004;25:1330-1340.
46. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation. 2000;102:399-404.
47. Heublein B, Rohde R, Kaese V, et al. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003;89:651-656.